Report cover image

Generics in the United States

Publisher MarketLine
Published Dec 18, 2025
Length 48 Pages
SKU # MTLN20937057

Description

Generics in the United States

Summary

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
  • The US generics market recorded revenues of $74.1 billion in 2024, representing a compound annual growth rate (CAGR) of 4.7% between 2019 and 2024.
  • Market consumption volumes declined with a negative CAGR of 0% between 2019 and 2024, reaching a total of 90.8% of total pharma volume in 2024.
  • In 2024, the revenue of the US generics market experienced an annual growth of 5.1%. The market’s growth is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions, increasing the demand for affordable, long-term medications.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United States
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts
Reasons to Buy
  • What was the size of the United States generics market by value in 2024?
  • What will be the size of the United States generics market in 2029?
  • What factors are affecting the strength of competition in the United States generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up the United States's generics market?

Table of Contents

48 Pages
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do the leading players follow?
7.3. What are the recent developments in the market?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Ltd
8.2. Viatris Inc
8.3. Pfizer Inc
8.4. Sandoz Group AG
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: United States generics market value: $ million, 2019-24
Table 2: United States generics market volume: % of total pharma volume, 2019-24
Table 3: United States generics market geography segmentation: $ million, 2024
Table 4: United States generics market value forecast: $ million, 2024-29
Table 5: United States generics market volume forecast: % of total pharma volume, 2024-29
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Viatris Inc: Key Facts
Table 10: Viatris Inc: Annual Financial Ratios
Table 11: Viatris Inc: Key Employees
Table 12: Pfizer Inc: Key Facts
Table 13: Pfizer Inc: Annual Financial Ratios
Table 14: Pfizer Inc: Key Employees
Table 15: Pfizer Inc: Key Employees Continued
Table 16: Sandoz Group AG: Key Facts
Table 17: Sandoz Group AG: Annual Financial Ratios
Table 18: Sandoz Group AG: Key Employees
Table 19: United States Size of Population (Million), 2020-24
Table 20: United States Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 21: United States GDP (Current Prices, $ Billion), 2020-24
Table 22: United States Inflation, 2020-24
Table 23: United States Consumer Price Index (Absolute), 2020-24
Table 24: United States Exchange Rate, 2019-24
List of Figures
Figure 1: United States generics market value: $ million, 2019-24
Figure 2: United States generics market volume: % of total pharma volume, 2019-24
Figure 3: United States generics market geography segmentation: % share, by value, 2024
Figure 4: United States generics market value forecast: $ million, 2024-29
Figure 5: United States generics market volume forecast: % of total pharma volume, 2024-29
Figure 6: Forces driving competition in the generics market in the United States, 2024
Figure 7: Drivers of buyer power in the generics market in the United States, 2024
Figure 8: Drivers of supplier power in the generics market in the United States, 2024
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2024
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2024
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2024

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.